Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21857964 | 1.00 | AR (0.35) | ARHTT | |
| SCHEMBL21857956 | 0.90 | AR (0.34) | ARHTT | |
| SCHEMBL21857898 | 0.89 | — | — | |
| SCHEMBL29913479 | 0.89 | — | — | |
| SCHEMBL30939546 | 0.86 | AR (0.42) | ARHTT | |
| SCHEMBL9901069 | 0.86 | AR (0.42) | ARHTT | |
| SCHEMBL21857668 | 0.84 | AR (0.32) | AR | |
| SCHEMBL9901048 | 0.82 | AR (0.41) | ARHTT | |
| SCHEMBL30939572 | 0.82 | AR (0.41) | ARHTT | |
| SCHEMBL21953283 | 0.82 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115066424-B | Kv3 modulators | 奥蒂福尼疗法有限公司 | 2024-12-27 | — | — | CN | claimed |
| EP-3867247-B1 | NOVEL COMPOUNDS | AUTIFONY THERAPEUTICS LTD (GB) | 2024-07-24 | — | — | EP | claimed |
| EP-4100402-A1 | KV3 MODULATORS | Autifony Therapeutics Limited (GB) | 2022-12-14 | — | — | EP | claimed |
| CN-115066424-A | Kv3 modulators | 奥蒂福尼疗法有限公司 | 2022-09-16 | — | — | CN | claimed |
| US-20250304564-A1 | NOVEL KV3 MODULATORS | AUTIFONY THERAPEUTICS LTD (GB) | 2025-10-02 | — | — | US | disclosed |
| US-12358901-B2 | KV3 modulators | AUTIFONY THERAPEUTICS LIMITED (GB) | 2025-07-15 | — | — | US | disclosed |
| CN-115066424-B | Kv3 modulators | 奥蒂福尼疗法有限公司 | 2024-12-27 | — | — | CN | disclosed |
| EP-4100402-A1 | KV3 MODULATORS | Autifony Therapeutics Limited (GB) | 2022-12-14 | — | — | EP | disclosed |
| CN-115066424-A | Kv3 modulators | 奥蒂福尼疗法有限公司 | 2022-09-16 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12358901-B2 | KV3 modulators | KCNN3, KCNA3, KCNH3 | AR 1889/4885HTT 3638/4885 |
| US-20250304564-A1 | NOVEL KV3 MODULATORS | KCNN3, KCNA3, KCND3 | AR 2073/4885HTT 3668/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.